Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

749 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches.
Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, Lacoeuille F, Drui D, Arlicot N, Goldenberg DM, Faivre-Chauvet A, Barbet J, Rousseau C, Kraeber-Bodéré F. Bodet-Milin C, et al. Among authors: goldenberg dm. Front Med (Lausanne). 2019 Jun 4;6:124. doi: 10.3389/fmed.2019.00124. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31214593 Free PMC article. Review.
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Rousseau C, Goldenberg DM, Colombié M, Sébille JC, Meingan P, Ferrer L, Baumgartner P, Cerato E, Masson D, Campone M, Rauscher A, Fleury V, Labbe C, Chauvet AF, Fresnel JS, Toquet C, Barbet J, Sharkey RM, Campion L, Kraeber-Bodéré F. Rousseau C, et al. Among authors: goldenberg dm. J Nucl Med. 2020 Aug;61(8):1205-1211. doi: 10.2967/jnumed.119.236000. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169921 Free PMC article. Clinical Trial.
A pretargeting system for tumor PET imaging and radioimmunotherapy.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Frampas E, Faivre-Chauvet A, Rauscher A, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. Among authors: goldenberg dm. Front Pharmacol. 2015 Mar 31;6:54. doi: 10.3389/fphar.2015.00054. eCollection 2015. Front Pharmacol. 2015. PMID: 25873896 Free PMC article. Review.
Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients.
Bodet-Milin C, Ferrer L, Rauscher A, Masson D, Rbah-Vidal L, Faivre-Chauvet A, Cerato E, Rousseau C, Hureaux J, Couturier O, Salaün PY, Goldenberg DM, Sharkey RM, Kraeber-Bodéré F, Barbet J. Bodet-Milin C, et al. Among authors: goldenberg dm. Front Med (Lausanne). 2015 Nov 27;2:84. doi: 10.3389/fmed.2015.00084. eCollection 2015. Front Med (Lausanne). 2015. PMID: 26640780 Free PMC article.
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
Bodet-Milin C, Faivre-Chauvet A, Carlier T, Ansquer C, Rauscher A, Frampas E, Toulgoat F, Masson D, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F. Bodet-Milin C, et al. Among authors: goldenberg dm. J Nucl Med. 2021 Sep 1;62(9):1221-1227. doi: 10.2967/jnumed.120.252791. Epub 2021 Feb 5. J Nucl Med. 2021. PMID: 33547213 Free PMC article.
Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
Touchefeu Y, Bailly C, Frampas E, Eugène T, Rousseau C, Bourgeois M, Bossard C, Faivre-Chauvet A, Rauscher A, Masson D, David A, Cerato E, Carlier T, Sharkey RM, Goldenberg DM, Barbet J, Kraeber-Bodere F, Bodet-Milin C. Touchefeu Y, et al. Among authors: goldenberg dm. Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):874-882. doi: 10.1007/s00259-020-04989-3. Epub 2020 Aug 21. Eur J Nucl Med Mol Imaging. 2021. PMID: 32820369
Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
Bodet-Milin C, Faivre-Chauvet A, Carlier T, Rauscher A, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F. Bodet-Milin C, et al. Among authors: goldenberg dm. J Nucl Med. 2016 Oct;57(10):1505-1511. doi: 10.2967/jnumed.116.172221. Epub 2016 May 26. J Nucl Med. 2016. PMID: 27230928 Free article. Clinical Trial.
Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT.
Foubert F, Gouard S, Saï-Maurel C, Chérel M, Faivre-Chauvet A, Goldenberg DM, Barbet J, Bailly C, Bodet-Milin C, Carlier T, Kraeber-Bodéré F, Touchefeu Y, Frampas E. Foubert F, et al. Among authors: goldenberg dm. Oncotarget. 2018 Jun 8;9(44):27502-27513. doi: 10.18632/oncotarget.25514. eCollection 2018 Jun 8. Oncotarget. 2018. PMID: 29938001 Free PMC article.
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. Among authors: goldenberg dm. J Nucl Med. 2006 Feb;47(2):247-55. J Nucl Med. 2006. PMID: 16455630 Free article. Clinical Trial.
749 results